Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Cancer Immunotherapy (Payer): Update Bulletin [June 2016]

Product Code:
596200538
Publication Date:
June 2016
Format:
PDF
Price:
£1,140

Gain new payer insights on the latest events with the potential to shape the cancer immunotherapy market. In this update, payers give their perspective on the potential reimbursement and coverage of Roche’s Tecentriq (atezolizumab), which was recently approved for the treatment of advanced bladder cancer; discuss the coverage of Bristol-Myers Squibb’s Opdivo (nivolumab) for classical Hodgkin lymphoma (cHL); and comment on the potential feasibility of companies partially reimbursing healthcare providers if patients don’t adequately respond to cancer therapies, or if patients require treatment for longer than expected.

Key Questions Answered in this Update Bulletin:

  • How do payers view the accelerated approval of Roche’s Tecentriq (atezolizumab) for the treatment of locally advanced or metastatic urothelial carcinoma?
  • How widely will the use of Tecentriq be funded, and what will be the approach to reimbursement of Tecentriq?
  • What strategies could be used to contain the costs of Tecentriq?
  • How do payers view the accelerated FDA approval Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of classical Hodgkin lymphoma (cHL)?
  • How widely will payers fund the use of Opdivo for cHL, and what will be the approach to reimbursement?
  • Will there be any differences in Opdivo coverage for cHL, non-small cell lung cancer (NSCLC), melanoma and renal cell carcinoma (RCC)?
  • How will the funding of Merck & Co.’s Keytruda (pembrolizumab) compare with that of Opdivo for the treatment of cHL, given that both these drugs have similar clinical data?
  • How do payers view the potential feasibility of companies partially reimbursing healthcare providers if patients don’t adequately respond to cancer therapies, or if patients require the treatment for longer than expected, and what factors will be key to the success of such agreements?
  • How will budget limitations impact the potential introduction of outcome-based risk-sharing agreements?
  • How will risk-sharing agreements likely be received by payers and companies marketing immunotherapies?
  • How widely will risk-sharing agreements for cancer immunotherapies be adopted in the US?
  • What are the barriers to the use of risk-sharing agreements from a payer’s perspective?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved